DHC-1, a potent and selective PARP1 inhibitor, selectively inhibited PARP1 activity and showed efficacy in BRCA1-deficient breast cancer and BRCA2-deficient pancreatic cancer cell lines (Table 2). Here, BRCA2 is linked to breast carcinoma.